Odyssey Therapeutics posts September 2026 corporate presentation with OD-001 and OD-002 data
Odyssey Therapeutics furnished a corporate presentation on Form 8-K, posted to its website on September 8, 2026. The deck covers Phase 2a monotherapy data for its oral RIPK2 inhibitor OD-001 in ulcerative colitis and preclinical data for its SLC15A4 inhibitor OD-002, and states $433 million in cash as of June 30, 2026, with runway into the second half of 2028. The filing contains no financial results, guidance, or new contracts; the presentation is company-prepared and its data are described as ongoing and subject to change.
Key points
- Balance sheet of $433 million as of June 30, 2026, expected to fund operations into H2 2028
- OD-001 Phase 2a monotherapy: 27% clinical remission rate in moderate-to-severe UC patients, with a -2.6 change in MMCS (p < 0.001), per presentation
- Next OD-001 data disclosure expected at UEG in October 2026; OD-002 CTA filing expected in H2 2026
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.